Aurobindo Pharma
₹1,087.05
-27.45 (-2.46%)
- Advice
- Hold
19 April, 2024 16:37 BSE: 524804
NSE: AUROPHARMAISIN: INE406A01037
Start SIP in Aurobindo Pharma
Start SIPAurobindo Pharma Performance
Day Range
- Low 1,079
- High 1,109
52 Week Range
- Low 575
- High 1,177
- Open Price1,109
- Previous Close1,115
- Volume1304443
Aurobindo Pharma F&O
Aurobindo Pharma Financials
| Indicator | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 2,664 | 2,648 | 2,364 | 3,484 |
| Operating Expenses Qtr Cr | 2,210 | 2,124 | 1,968 | 2,856 |
| Operating Profit Qtr Cr | 482 | 545 | 422 | 692 |
| Depreciation Qtr Cr | 64 | 66 | 60 | 115 |
| Interest Qtr Cr | 61 | 37 | 32 | 49 |
| Tax Qtr Cr | 63 | 130 | 90 | 171 |
| Net Profit Qtr Cr | 624 | 416 | 336 | 645 |
Aurobindo Pharma Technicals
EMA & SMA
Current Price
₹1,087.05
-27.45 (-2.46%)
- Bullish Moving Average
- ___
- 10
- Bearish Moving Average
- ___
- 6
- 20 Day
- ₹1,090.44
- 50 Day
- ₹1,070.91
- 100 Day
- ₹1,039.11
- 200 Day
- ₹953.32
- 20 Day
- ₹1,082.27
- 50 Day
- ₹1,053.29
- 100 Day
- ₹1,065.88
- 200 Day
- ₹960.14
Aurobindo Pharma Resistance and Support
PIVOT
₹1,113.1
| Resistance | |
|---|---|
| First Resistance | 1,130.40 |
| Second Resistance | 1,146.30 |
| Third Resistance | 1,163.60 |
| RSI | 57.79 |
| MFI | 58.65 |
| MACD Single Line | 16.11 |
| MACD | 16.62 |
| Support | |
|---|---|
| First Resistance | 1,097.20 |
| Second Resistance | 1,079.90 |
| Third Resistance | 1,064.00 |
Aurobindo Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 2,098,648 | 133,264,148 | 63.5 |
| Week | 1,941,677 | 104,578,723 | 53.86 |
| 1 Month | 1,837,699 | 84,111,476 | 45.77 |
| 6 Month | 2,553,221 | 114,946,012 | 45.02 |
Aurobindo Pharma Result Highlights
Aurobindo Pharma Synopsis
NSE-Medical-Generic Drugs
Aurobindo Pharma is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 12792.28 Cr. and Equity Capital is Rs. 58.59 Cr. for the Year ended 31/03/2023. Aurobindo Pharma Ltd. is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190.| Market Cap | 63,264 |
| Sales | 11,299 |
| Shares in Float | 28.12 |
| No of funds | 727 |
| Yield | 0.41 |
| Book Value | 3.65 |
| U/D Vol ratio | 0.9 |
| LTDebt / Equity | |
| Alpha | 0.19 |
| Beta | 0.68 |
Aurobindo Pharma
| Owner Name | Mar-24 | Dec-23 | Sep-23 | Jun-23 |
|---|---|---|---|---|
| Promoters | 51.83% | 51.83% | 51.83% | 51.83% |
| Mutual Funds | 17.83% | 14.7% | 11.27% | 8.37% |
| Insurance Companies | 5.03% | 5.53% | 6.67% | 7.03% |
| Foreign Portfolio Investors | 18.01% | 20.72% | 22.45% | 24.12% |
| Financial Institutions/ Banks | ||||
| Individual Investors | 5.51% | 5.65% | 6.16% | 7.02% |
| Others | 1.79% | 1.57% | 1.62% | 1.63% |
Aurobindo Pharma Management
| Name | Designation |
|---|---|
| Mr. K Ragunathan | Non Exe.Chairman&Ind.Director |
| Mr. K Nithyananda Reddy | Vice Chairman & Mng.Director |
| Dr. M Sivakumaran | Whole Time Director |
| Mr. M Madan Mohan Reddy | Whole Time Director |
| Mr. P V Ramprasad Reddy | Non Executive Director |
| Mrs. Savita Mahajan | Independent Director |
| Mr. Girish P Vanvari | Independent Director |
| Dr.(Mrs.) Avnit Bimal Singh | Independent Director |
| Mr. Santanu Mukherjee | Independent Director |
Aurobindo Pharma Forecast
Price Estimates
2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)
Aurobindo Pharma Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-02-10 | Quarterly Results & Interim Dividend | |
| 2023-11-09 | Quarterly Results & Interim Dividend | |
| 2023-08-12 | Quarterly Results | |
| 2023-05-27 | Audited Results | |
| 2023-02-09 | Quarterly Results & Interim Dividend |
| Date | Purpose | Remarks |
|---|---|---|
| 2024-02-20 | INTERIM | Rs.1.50 per share(150%)Second Interim Dividend |
| 2023-11-20 | INTERIM | Rs.3.00 per share(300%)First Interim Dividend |
| 2023-02-17 | INTERIM | Rs.3.00 per share(300%)Interim Dividend |
| 2022-06-07 | INTERIM | Rs.4.50 per share (450%) Fourth Interim Dividend |
| 2022-02-21 | INTERIM | Rs.1.50 per share(150%)Third Interim Dividend |
Aurobindo Pharma FAQs
What is Share Price of Aurobindo Pharma ?
Aurobindo Pharma share price is ₹1,087 As on 19 April, 2024 | 16:23
What is the Market Cap of Aurobindo Pharma ?
The Market Cap of Aurobindo Pharma is ₹63694.5 Cr As on 19 April, 2024 | 16:23
What is the P/E ratio of Aurobindo Pharma ?
The P/E ratio of Aurobindo Pharma is 23 As on 19 April, 2024 | 16:23
What is the PB ratio of Aurobindo Pharma ?
The PB ratio of Aurobindo Pharma is 2.4 As on 19 April, 2024 | 16:23
Is it a good time to invest in Aurobindo Pharma?
Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.
How many times have Aurobindo Pharma given dividends since 2000?
Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.
What is the stock price CAGR of Aurobindo Pharma?
The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.
What is the ROE of Aurobindo Pharma?
Aurobindo Pharma has an ROE of 24% which is exceptional.
What is Aurobindo Pharma’s debt to equity?
Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.